Affimed Formed a Research Collaboration with Genentech for Novel NK Cells

 Affimed Formed a Research Collaboration with Genentech for Novel NK Cells

Affimed Formed a Research Collaboration with Genentech for Novel NK Cells

Shots:
  • The collaboration is for development and commercialization of novel NK cell engager-based immunotherapeutics to treat multiple cancers
  •  Affimed’s will use its ROCK platform (Redirected Optimized Cell Killing) to develop NK cell and T cell-engaging Abs and Genentech will take care of all global clinical development and commercialization
  •  Affimed to receive an upfront $96M and additional payment of up to $5.0B including specified development, regulatory and commercial milestones with royalties on sales, with expected closure in Q3’18

Click here to read full press release/ article | Ref: Affimed | Image:  Sec filling

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post